eHealthSocial Media

Cancer Patient’s Social Media Crusade Reaches “Compassionate Use” Victory

2 Mins read

compassionate useOriginally published on MedCityNews.com. The white knight moment has come for a Texas lawyer who has spent the past two months amassing an “army” of virtual supporters in her quest for access to an experimental cancer drug. Only the turnout isn’t exactly as she had imagined.

compassionate useOriginally published on MedCityNews.com. The white knight moment has come for a Texas lawyer who has spent the past two months amassing an “army” of virtual supporters in her quest for access to an experimental cancer drug. Only the turnout isn’t exactly as she had imagined.

Andrea Sloan, who has gathered nearly 210,000 signatures on a petition to BioMarin Pharmaceutical, posted a video on her Facebook page on Thursday expressing gratitude toward her supporters and an unnamed company who she said stepped in to provide her with access to an experimental cancer drug under “compassionate use.”

Sloan had originally reached out to BioMarin requesting access to BMN673, the company’s not-yet-FDA-approved cancer drug which it said shrunk the tumors of 11 out of 25 ovarian cancer patients by at least 30 percent in a recent Phase 1/2 trial. Her doctors had recommended the drug when her ovarian cancer reappeared after several rounds of chemotherapy, two rounds of radiation and five surgeries.

The FDA allows drug companies to give experimental drugs to patients outside of clinical trials if the patient meets certain requirements, which Sloan said she did. But BioMarin had turned down her request, saying in a letter it was “too early to know if the experimental therapy is safe or effective, or will even prolong life.” That was when the social media war began.

In her video, Sloan said a competing pharmaceutical company developing a drug of the same class, a PARP inhibitor, came to the rescue. She said she was now taking a medication that she was sure would help extend her life. The company providing it likely asked for anonymity to avoid being put under a microscope the same way BioMarin was as a result of the campaign.

In a separate video posted on her Facebook, Sloan tells BioMarin that the fight isn’t over. “I did want to let you know that we’re not dead,” she says. “This has always been about compassionate use reform for everyone.”

 

Related posts
eHealth

What Are The Benefits Of Wearable Technology In Healthcare?

5 Mins read
For one, at least two motives wearable technology in health care has come to stay and certainly holds the promise for the…
eHealthMobile HealthTechnology

Technologies That Can Help You Keep Track of Your Health

3 Mins read
Here and now in the digital age, technology plays a vital role in nearly every part of life. Because maintaining a healthy…
eHealth

How Is Remote Therapy Helping Patients During the Covid-19 Pandemic?

3 Mins read
During the COVID-19 pandemic, telehealth saw a huge surge in popularity as patients did their best to avoid in-person appointments whenever possible…